```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653adk

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *  Welcome to STN International  * * * * * * * * *
* *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  Jul 12  BEILSTEIN enhanced with new display and select
options,
                  resulting in a closer connection to BABS
 NEWS  4  AUG 02  IFIPAT/IFIUDB/IFICDB reloaded with new search and
display
                  fields
 NEWS  5  AUG 02  CAplus and CA patent records enhanced with European
and Japan
                  Patent Office Classifications
 NEWS  6  AUG 02  The Analysis Edition of STN Express with Discover!
                  (Version 7.01 for Windows) now available
 NEWS  7  AUG 27  BIOCOMMERCE: Changes and enhancements to content
coverage
 NEWS  8  AUG 27  BIOTECHABS/BIOTECHDS: Two new display fields added
for legal
                  status data from INPADOC
 NEWS  9  SEP 01  INPADOC: New family current-awareness alert (SDI)
available
 NEWS 10  SEP 01  New pricing for the Save Answers for SciFinder
Wizard within
                  STN Express with Discover!
 NEWS 11  SEP 01  New display format, HITSTR, available in
WPIDS/WPINDEX/WPIX
 NEWS 12  SEP 27  STANDARDS will no longer be available on STN
 NEWS 13  SEP 27  SWETSCAN will no longer be available on STN

 NEWS EXPRESS  JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to
STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to
scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *
* *

FILE 'HOME' ENTERED AT 11:32:37 ON 23 OCT 2004

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE
TOTAL
                                                      ENTRY
SESSION
FULL ESTIMATED COST                                    0.21
0.21

FILE 'REGISTRY' ENTERED AT 11:32:52 ON 23 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 OCT 2004  HIGHEST RN 767117-28-2
DICTIONARY FILE UPDATES:  21 OCT 2004  HIGHEST RN 767117-28-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for
details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading H:\STN queries\09879442.str
```



```
chain nodes :
19  20  21  22  23  24  31  32  33  34  35  36  37  38  39  40  41
42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58
59  60  61  62  63  64  65  66  67  68  69  70  71  72
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  25  26
27  28  29  30
chain bonds :
6-21  7-19  10-20  11-72  14-23  16-67  16-68  18-24  21-22  24-28
25-32  26-33  30-31  31-34  34-35  34-36  36-37  36-41  37-38  38-39
38-40  41-42  42-43  42-44  43-45  43-54  46-51  46-47  46-55  47-48
48-49  48-50  51-52  52-53  52-57  54-55  55-56  57-58  58-59  59-60
60-61  60-62  62-63  63-64  64-65  64-66  67-69  67-70  70-71
ring bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  8-11  9-10  9-14
11-12  12-13  12-15  13-14  13-18  15-16  16-17  17-18  25-26  25-30
26-27  27-28  28-29  29-30
exact/norm bonds :
4-7  5-10  6-21  7-8  7-19  9-10  10-20  11-72  12-15  13-18  14-23
15-16  16-17  16-68  17-18  18-24  21-22  24-28  25-26  25-30  25-32
26-27  27-28  28-29  29-30  30-31  31-34  34-35  36-41  41-42  42-44
43-54  46-51  51-52  52-53  54-55  55-56  58-59  59-60  60-61  64-65
64-66  67-69  70-71
exact bonds :
16-67  26-33  34-36  36-37  37-38  38-39  38-40  42-43  43-45  46-47
46-55  47-48  48-49  48-50  52-57  57-58  60-62  62-63  63-64  67-70
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  8-9  8-11  9-14  11-12  12-13  13-14

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom
9:Atom  10:Atom  11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom
17:Atom  18:Atom  19:CLASS  20:CLASS  21:CLASS  22:CLASS  23:CLASS
24:CLASS  25:Atom  26:Atom  27:Atom  28:Atom  29:Atom  30:Atom
31:CLASS  32:CLASS  33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS
38:CLASS  39:CLASS  40:CLASS  41:CLASS  42:CLASS  43:CLASS  44:CLASS
45:CLASS  46:CLASS  47:CLASS  48:CLASS  49:CLASS  50:CLASS  51:CLASS
52:CLASS  53:CLASS  54:CLASS  55:CLASS  56:CLASS  57:CLASS  58:CLASS
59:CLASS  60:CLASS  61:CLASS  62:CLASS  63:CLASS  64:CLASS  65:CLASS
66:CLASS  67:CLASS  68:CLASS  69:CLASS  70:CLASS  71:CLASS  72:CLASS


L1      STRUCTURE UPLOADED

=> s l1 sam fam
SAMPLE SEARCH INITIATED 11:33:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      7 TO ITERATE

100.0% PROCESSED       7 ITERATIONS                                 0
ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
PROJECTED ITERATIONS:            7 TO       298
PROJECTED ANSWERS:               0 TO         0

L2            0 SEA FAM SAM L1

=> s l1 ful
FULL SEARCH INITIATED 11:33:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    715 TO ITERATE

100.0% PROCESSED     715 ITERATIONS                                 4
ANSWERS
SEARCH TIME: 00.00.01

L3            4 SEA SSS FUL L1
```

=> d l3 1-4 ide ibib

L3 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 372491-73-1 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-
leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-
1-methoxy-, monosodium salt, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C49 H65 N5 O18 . Na
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
DT.CA CAplus document type: Journal
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)
CRN (274912-87-7)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



● Na



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 135:362468 CA Full-text
TITLE: N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity
AUTHOR(S): Dasnois, Luc; Lebtahi, Karim; Dubois, Vincent; Lobl, Thomas J.; Gangwar, Sanjeev; Oliyai, Cecilia; Lewis, Evan R.; Shochat, Dan; Trouet, Andre
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Journal of Medicinal Chemistry (2001), 44(22), 3750-3753
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274913-07-4 REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(4-methoxy-1,4-
dioxobutyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH
MF C50 H67 N5 O18
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); RACT
(Reactant or reagent); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 138:29142 CA Full-text
TITLE: CD10-activated prodrug compounds
INVENTOR(S): Bebbington, Christopher R.; Nieder, Matthew H.; Pickford, Lesley B.; Pan, Chin Cardarelli, Pina M.; Gangwar, Sanjeev;
PATENT ASSIGNEE(S): Medarex, Inc., USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100353	A2	20021219	WO 2002-US21135	20020610
WO 2002100353	A3	20030522		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1404356	A2	20040407	EP 2002-746852	20020611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004087497	A1	20040506	US 2002-167627	20020611
PRIORITY APPLN. INFO.:			US 2001-297596P	20010611
			WO 2002-US21135	20020611

REFERENCE 2

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1144011 A2 20011017 EP 1999-967462 19991210
EP 1144011 A3 20020206
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2003518000 T2 20030603 JP 2000-586378 19991210
AU 773420 B2 20040527 AU 2000-23733 19991210
US 2002142955 A1 20021003 US 2001-879442 20010611

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L3 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274913-03-0 REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[1,4-dioxo-4-(2-propenyloxy)butyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C52 H69 N5 O18
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,





7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:156884 CA Full-text
TITLE: CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10+ Tumors
AUTHOR(S): Pan, Chin; Cardarelli, Pina M.; Nieder, Matthew H.; Pickford, Lesley B.; Gangwar, Sanjeev; King, David J.; Yarranton, Geoffrey T.; Buckman, Dana; Roscoe, William; Zhou, Fengmin; Salles, Adam; Chen, Tseng-Hui; Horgan, Killian; Wang, Yi-Hong; Nguyen, Thi; Bebbington, Christopher R.
CORPORATE SOURCE: Corixa Corp., South San Francisco, CA, 94080, USA
SOURCE: Cancer Research (2003), 63(17), 5526-5531
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 2

ACCESSION NUMBER: 138:29142 CA Full-text
TITLE: CD10-activated prodrug compounds
INVENTOR(S): Bebbington, Christopher R.; Nieder, Matthew H.; Cardarelli, Pina M.; Gangwar, Sanjeev; Pickford, Lesley B.; Pan, Chin
PATENT ASSIGNEE(S): Medarex, Inc., USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100353	A2	20021219	WO 2002-US21135	20020610
WO 2002100353	A3	20030522		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1404356	A2	20040407	EP 2002-746852	20020611

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2004087497	A1	20040506	US 2002-167627	20020611

PRIORITY APPLN. INFO.: US 2001-297596P 20010611
WO 2002-US21135 20020611

REFERENCE 3

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 1998-111793P	19981211
US 1999-119312P	19990208
WO 1999-US30393	19991210
US 2000-211887P	20000614
US 2001-290448P	20010511

REFERENCE 4

ACCESSION NUMBER: 137:241802 CA Full-text
TITLE: CPI-0004Na, a new extracellularly tumor-

activated prodrug of Doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity
AUTHOR(S): Dubois, Vincent; Dasnois, Luc; Lebtahi, Karim; Collot, Francoise; Heylen, Nathalie; Havaux, Nathalie; Fernandez, Anne-Marie; Lobl, Thomas J.; Oliyai, Cecilia; Nieder, Matthew; Shochat, Dan; Yarranton, Geoffrey T.; Trouet, Andre
CORPORATE SOURCE: Universite Catholique de Louvain, Laboratory of Cell Biology, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Cancer Research (2002), 62(8), 2327-2331
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 5

ACCESSION NUMBER: 136:86054 CA Full-text
TITLE: Tripeptide prodrug compounds
INVENTOR(S): Bebbington, Christopher R.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000263	A2	20020103	WO 2001-US40925	20010611
WO 2002000263	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1294403	A2	20030326	EP 2001-942249	20010611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004501875	T2	20040122	JP 2002-505044	20010611
US 2003181359	A1	20030925	US 2002-311519	20021213
PRIORITY APPLN. INFO.:			US 2000-212880P	20000614
			WO 2001-US40925	20010611

REFERENCE 6

ACCESSION NUMBER: 136:58787 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Nieder, Matthew H.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095945	A2	20011220	WO 2001-US18903	20010611
WO 2001095945	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1294405	A2	20030326	EP 2001-950291	20010611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004510703	T2	20040408	JP 2002-510122	20010611
PRIORITY APPLN. INFO.:			US 2000-211887P	20000614
			US 2001-290448P	20010511
			WO 2001-US18903	20010611

REFERENCE 7

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
PRIORITY APPLN. INFO.:			US 1998-111793P	19981211
			US 1999-119312P	19990208
			WO 1999-US30393	19991210
			US 2000-211887P	20000614
			US 2001-290448P	20010511

```
=> FIL HCAPLUS
COST IN U.S. DOLLARS                        SINCE FILE
TOTAL                                         ENTRY

SESSION                                      168.64
FULL ESTIMATED COST
168.85

FILE 'HCAPLUS' ENTERED AT 11:36:28 ON 23 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 23 Oct 2004  VOL 141 ISS 18
FILE LAST UPDATED: 22 Oct 2004  (20041022/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> d his

     (FILE 'HOME' ENTERED AT 11:32:37 ON 23 OCT 2004)

     FILE 'REGISTRY' ENTERED AT 11:32:52 ON 23 OCT 2004
L1             STRUCTURE UPLOADED
L2               0 S L1 SAM FAM
L3               4 S L1 FUL

     FILE 'HCAPLUS' ENTERED AT 11:36:28 ON 23 OCT 2004

=> s l3
L4               8 L3

=> d l4 1-8 ibib abs

L4   ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2003:733803  HCAPLUS Full-text
DOCUMENT NUMBER:          140:156884
```

TITLE: CD10 Is a Key Enzyme Involved in the Activation of Tumor-activated Peptide Prodrug CPI-0004Na and Novel Analogues: Implications for the Design of Novel Peptide Prodrugs for the Therapy of CD10+ Tumors
AUTHOR(S): Pan, Chin; Cardarelli, Pina M.; Nieder, Matthew H.; Pickford, Lesley B.; Gangwar, Sanjeev; King, David J.; Yarranton, Geoffrey T.; Buckman, Dana; Roscoe, William; Zhou, Fengmin; Salles, Adam; Chen, Tseng-Hui; Horgan, Killian; Wang, Yi-Hong; Nguyen, Thi; Bebbington, Christopher R.
CORPORATE SOURCE: Corixa Corp., South San Francisco, CA, 94080, USA
SOURCE: Cancer Research (2003), 63(17), 5526-5531
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Traditional chemotherapeutic drugs are often restricted by severe side effects and lack of tumor specificity. Peptide prodrugs cleavable by peptidases present in the tumor environment have been explored to improve the therapeutic index of cytotoxic drugs. One such prodrug of doxorubicin (Dox), CPI-0004Na [N-succinyl-β-alanyl-L-leucyl-L-alanyl-L-leucyl-Dox (sALAL-Dox)] has been shown to have an improved antitumor efficacy profile with reduced toxicity compared with Dox in tumor xenograft models (V. Dubois et al., Cancer Res., 62: 2327-2331, 2002). In this study, we demonstrate that CD10, a cell surface metalloprotease expressed on a variety of tumor cell types, is capable of cleaving CPI-0004Na and related peptide prodrugs such as N-succinyl-β-alanyl-L-isoleucyl-L-alanyl-L-leucyl-Dox (sAIAL-Dox). This proteolytic cleavage generates leucyl-Dox, which is capable of entering cells and generating intracellular Dox. In a [3H]thymidine proliferation assay, analogs of CPI-0004Na showed a 100-300-fold increase in potency on CD10+ cells compared with CD10- cells. Cytotoxicity of CPI-0004Na was inhibited by phosphoramidon, a known inhibitor of CD10 enzymic activity. Furthermore, Chinese hamster ovary CHO-S cells, which are resistant to CPI-0004Na, could be sensitized to the cytotoxic effect of the prodrug by transfection of a CD10 cDNA. Tumor xenograft studies using LNCaP prostate tumor cells support the important role of CD10 in the antitumor efficacy of these prodrugs against tumors expressing CD10. CPI-0004Na and sAIAL-Dox achieved statistically significant 70% tumor growth inhibition at day 22. CD10 is expressed on many types of human tumors including B-cell lymphoma, leukemia, and prostate, breast, colorectal, and lung carcinomas; therefore, CD10-cleavable prodrugs may be effective in a range of different tumor types.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:964147 HCAPLUS Full-text
DOCUMENT NUMBER: 138:29142
TITLE: CD10-activated prodrug compounds
INVENTOR(S): Bebbington, Christopher R.; Nieder, Matthew H.; Cardarelli, Pina M.; Gangwar, Sanjeev; Pickford, Lesley B.; Pan, Chin
PATENT ASSIGNEE(S): Medarex, Inc., USA
SOURCE: PCT Int. Appl., 167 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100353	A2	20021219	WO 2002-US21135	20020610
WO 2002100353	A3	20030522		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1404356	A2	20040407	EP 2002-746852	20020611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004087497	A1	20040506	US 2002-167627	20020611
PRIORITY APPLN. INFO.:			US 2001-297596P	P 20010611
			WO 2002-US21135	W
			US 1998-111793P	P 19981211
			US 1999-119312P	P 19990208
			WO 1999-US30393	A2 19991210
			US 2000-211887P	P 20000614
			US 2001-290448P	P 20010511

OTHER SOURCE(S): MARPAT 138:29142

AB The compds. of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed. For example, a tetrapeptide prodrug, Suc-βAla-Ile-Ala-Leu-Dox (preparation given), was better tolerated in mice than doxorubicin. The prodrug was efficacious in mice bearing doxorubicin-resistant human colorectal carcinoma at a dose of 53 or 68 mg/kg (equivalent to 30 or 38 mg/kg doxorubicin) at 5 days intervals for a total of five identical doses. Doxorubicin alone, at its tolerated dose (3 mg/kg), under this dosing regimen, is historically ineffective.

L4 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:755199 HCAPLUS Full-text
DOCUMENT NUMBER: 137:284323
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1998-111793P	P 19981211
			US 1999-119312P	P 19990208
			WO 1999-US30393	A2 19991210
			US 2000-211887P	P 20000614
			US 2001-290448P	P 20010511

OTHER SOURCE(S): MARPAT 137:284323

AB The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme Thimet oligopeptidase, or TOP. Also disclosed are methods of designing prodrugs by utilizing TOP-cleavable sequences within the conjugate and methods of treating patients with prodrugs of the invention.

L4 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:323079 HCAPLUS Full-text
DOCUMENT NUMBER: 137:241802
TITLE: CPI-0004Na, a new extracellularly tumor-activated prodrug of Doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity
AUTHOR(S): Dubois, Vincent; Dasnois, Luc; Lebtahi, Karim; Collot, Francoise; Heylen, Nathalie; Havaux, Nathalie; Fernandez, Anne-Marie; Lobl, Thomas J.; Oliyai, Cecilia; Nieder, Matthew; Shochat, Dan; Yarranton, Geoffrey T.; Trouet, Andre
CORPORATE SOURCE: Universite Catholique de Louvain, Laboratory of Cell Biology, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Cancer Research (2002), 62(8), 2327-2331
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The search for cancer therapies that are more selective for tumor cells and spare normal sensitive cells has been very active for at least 20 yr. The extracellularly tumor-activated

peptidic prodrug of doxorubicin (Dox) CPI-0004Na (N-succinyl-β-alanyl-L-leucyl-L-alanyl-L-leucyl-Dox) is potentially such a treatment. Here, we report the results of lethality studies performed with this compound in the mouse, showing that it is up to 4.6 times less toxic than Dox•HCl by the i.v. route and up to 16.2 times after i.p. administration. Pharmacokinetics and tissue distribution data indicate that this reduced toxicity is attributable to a lower uptake of Dox in normal tissues after treatment with CPI-0004Na than after the administration of a equimolar dose of Dox•HCl. For example, heart exposure to Dox is reduced > 10-fold. Because of this reduced toxicity, higher doses of CPI-0004Na than of the parent drug could be used to treat nude mice bearing s.c. human breast (MCF-7/6) and colon (LS-174-T and CXF-280/10) tumors. In all three models, the prodrug showed a much improved efficacy as compared with Dox•HCl. Particularly, LS-174-T tumors that do not respond to Dox were inhibited by 68% after treatment with CPI-0004Na. Tissue distribution studies performed with MCF-7/6 tumor-bearing nude mice and comparing CPI-0004Na and Dox•HCl confirmed that the improved activity of the prodrug is actually the result of selective generation and uptake of Dox at the tumor site. Dox levels in tumor tissue were 2-fold higher after treatment with CPI-0004Na than after treatment with an equimolar dose of Dox•HCl, whereas normal tissue levels were reduced 1.4-29-fold.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:10314 HCAPLUS Full-text
DOCUMENT NUMBER: 136:86054
TITLE: Tripeptide prodrug compounds
INVENTOR(S): Bebbington, Christopher R.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000263	A2	20020103	WO 2001-US40925	20010611
WO 2002000263	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1294403 A2 20030326 EP 2001-942249 20010611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004501875 T2 20040122 JP 2002-505044 20010611
US 2003181359 A1 20030925 US 2002-311519 20021213
PRIORITY APPLN. INFO.: US 2000-212880P P 20000614
WO 2001-US40925 W 20010611
OTHER SOURCE(S): CASREACT 136:86054; MARPAT 136:86054

AB The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide AA3-AA2-AA1 (AA1 is leucine, phenylalanine, isoleucine, alanine, glycine, tyrosine, 2-naphthylalanine, or serine; AA2 is alanine, leucine, tyrosine, glycine, serine, 3-pyridylalanine, 2-thienylalanine, aminoisobutyric acid, threonine, or phenylalanine; AA3 is leucine, sarcosine, tyrosine, phenylalanine, p-chloro- or p-nitrophenylalanine, valine, norleucine, norvaline, phenylglycine, tryptophan, tetrahydroisoquinoline-3-carboxylic acid, 3-pyridylalanine, alanine, glycine, 2-thienylalanine, methionine, or proline), a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Thus, Suc-Leu-Ala-Leu-Dox (Suc = succinic acid residue, Dox = doxorubicin residue), prepared by conjugation of doxorubicin hydrochloride with Fmoc-Leu-Ala-Leu-OH, deprotection, and acylation with succinic anhydride, showed tumor-activated prodrug activity on LNCaP, HT-29 and PC-3 cells of 0.016, 0.052, and 0.075 μM, resp. Suc-Leu-Ala-Leu-Dox is better tolerated in vivo than is doxorubicin.

L4 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:923644 HCAPLUS Full-text
DOCUMENT NUMBER: 136:58787
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Nieder, Matthew H.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095945	A2	20011220	WO 2001-US18903	20010611
WO 2001095945	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1294405 A2 20030326 EP 2001-950291 20010611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004510703 T2 20040408 JP 2002-510122 20010611
PRIORITY APPLN. INFO.: US 2000-211887P P 20000614
US 2001-290448P P 20010511
WO 2001-US18903 W 20010611
OTHER SOURCE(S): MARPAT 136:58787

AB The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme, thimet oligopeptidase (TOP). Also disclosed are methods of designing prodrugs by utilizing TOP-cleavage sequences within the conjugate and methods of treating patients with prodrugs of the invention.

L4 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:653068 HCAPLUS Full-text
DOCUMENT NUMBER: 135:362468
TITLE: N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity
AUTHOR(S): Fernandez, Anne-Marie; Van derpoorten, Kim; Dasnois, Luc; Lebtahi, Karim; Dubois, Vincent; Lobl, Thomas J.; Gangwar, Sanjeev; Oliyai, Cecilia; Lewis, Evan R.; Shochat, Dan; Trouet, Andre
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Journal of Medicinal Chemistry (2001), 44(22), 3750-3753
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB I.v. administration of N-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin induces an acute toxic reaction, killing animals in a few minutes. This results from its pos. charge at physiol. pH combined with its propensity to form large aggregates in aqueous solns. Neg. charged N-capped versions of N-(β-alanyl-L-leucyl-L-alanyl-L- leucyl)doxorubicin such as the succinyl derivative can be administered by the i.v. route at more than 10 times the LD50 of doxorubicin without inducing the acute toxic reaction, and they are active in vivo.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:401690 HCAPLUS Full-text
DOCUMENT NUMBER: 133:48878
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
PRIORITY APPLN. INFO.:			US 1998-111793P	P 19981211
			US 1999-119312P	P 19990208
			WO 1999-US30393	W 19991210
			US 2000-211887P	P 20000614
			US 2001-290448P	P 20010511

OTHER SOURCE(S): MARPAT 133:48878

AB The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the enzyme trouase. Also disclosed are processes for making the prodrug compds.

=>
Uploading H:\STN queries\09879442b.str



chain nodes :
19 20 21 22 23 24 31 32 33 34 35 36 37 38 39 40 41
42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58
59 60 61 62 63 64 65
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 25 26
27 28 29 30
chain bonds :
6-21 7-19 10-20 11-65 14-23 16-60 16-61 18-24 21-22 24-28
25-32 26-33 30-31 31-34 34-35 34-36 36-37 36-41 37-38 38-39
38-40 41-42 42-43 42-44 43-45 43-54 46-51 46-47 46-55 47-48
48-49 48-50 51-52 52-53 52-57 54-55 55-56 57-58 58-59 60-62
60-63 63-64
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 8-11 9-10 9-14
11-12 12-13 12-15 13-14 13-18 15-16 16-17 17-18 25-26 25-30
26-27 27-28 28-29 29-30
exact/norm bonds :
4-7 5-10 6-21 7-8 7-19 9-10 10-20 11-65 12-15 13-18 14-23
15-16 16-17 16-61 17-18 18-24 21-22 24-28 25-26 25-30 25-32
26-27 27-28 28-29 29-30 30-31 31-34 34-35 36-41 41-42 42-44
43-54 46-51 51-52 52-53 54-55 55-56 58-59 60-62 63-64
exact bonds :
16-60 26-33 34-36 36-37 37-38 38-39 38-40 42-43 43-45 46-47
46-55 47-48 48-49 48-50 52-57 57-58 60-63
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-11 9-14 11-12 12-13 13-14

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom
9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom
17:Atom 18:Atom 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS
24:CLASS 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS
38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS
45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS
52:CLASS 53:CLASS 54:CLASS 55:CLASS 56:CLASS 57:CLASS 58:CLASS
59:CLASS 60:CLASS 61:CLASS 62:CLASS 63:CLASS 64:CLASS 65:CLASS

L5 STRUCTURE UPLOADED

=> FIL REGISTRY
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY
SESSION
FULL ESTIMATED COST 41.64 210.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY
SESSION
CA SUBSCRIBER PRICE -5.60 -5.60

FILE 'REGISTRY' ENTERED AT 11:42:07 ON 23 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by Infochem.

STRUCTURE FILE UPDATES: 21 OCT 2004 HIGHEST RN 767117-28-2

DICTIONARY FILE UPDATES: 21 OCT 2004 HIGHEST RN 767117-28-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s l5 sam
SAMPLE SEARCH INITIATED 11:42:15 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 34 TO ITERATE

100.0% PROCESSED 34 ITERATIONS 1
ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 331 TO 1029
PROJECTED ANSWERS: 1 TO 80

L6 1 SEA SSS SAM L5

=> s l5 ful
FULL SEARCH INITIATED 11:42:21 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 715 TO ITERATE

100.0% PROCESSED 715 ITERATIONS 11
ANSWERS
SEARCH TIME: 00.00.01

L7 11 SEA SSS FUL L5

=> d his

(FILE 'HOME' ENTERED AT 11:32:37 ON 23 OCT 2004)

FILE 'REGISTRY' ENTERED AT 11:32:52 ON 23 OCT 2004
L1 STRUCTURE UPLOADED
L2 0 S L1 SAM FAM
L3 4 S L1 FUL

FILE 'HCAPLUS' ENTERED AT 11:36:28 ON 23 OCT 2004
L4 8 S L3
L5 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 11:42:07 ON 23 OCT 2004
L6 1 S L5 SAM
L7 11 S L5 FUL

=> l7 not l3
L8 7 L7 NOT L3

=> d l8 1-8 ide ibib

L8 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274913-06-3 REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C60 H71 N5 O17
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: PREP (Preparation); RACT (Reactant or reagent)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.





3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 1998-111793P	19981211
	US 1999-119312P	19990208
	WO 1999-US30393	19991210
	US 2000-211887P	20000614
	US 2001-290448P	20010511

REFERENCE 2

ACCESSION NUMBER: 135:362468 CA Full-text
TITLE: N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity
AUTHOR(S): Fernandez, Anne-Marie; Van derpoorten, Kim; Dasnois, Luc; Lebtahi, Karim; Dubois, Vincent; Lobl, Thomas J.; Gangwar, Sanjeev; Oliyai, Cecilia; Lewis, Evan R.; Shochat, Dan; Trouet, Andre
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Journal of Medicinal Chemistry (2001), 44(22), 3750-3753
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.:	US 1998-111793P	19981211
	US 1999-119312P	19990208
	WO 1999-US30393	19991210
	US 2000-211887P	20000614
	US 2001-290448P	20010511

L8 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274913-02-9 REGISTRY
CN Propanoic acid, 2-hydroxy-, compd. with (8S,10S)-10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5,12-Naphthacenedione, 10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-, mono(2-hydroxypropanoate) (salt) (9CI)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C45 H61 N5 O15 . C3 H6 O3
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

CM 1

CRN 177953-52-5
CMF C45 H61 N5 O15

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



CM 2

CRN 50-21-5
CMF C3 H6 O3



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 135:362468 CA Full-text
TITLE: N-succinyl-(β-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity
AUTHOR(S): Fernandez, Anne-Marie; Van derpoorten, Kim; Dasnois, Luc; Lebtahi, Karim; Dubois, Vincent; Lobl, Thomas J.; Gangwar, Sanjeev; Oliyai, Cecilia; Lewis, Evan R.; Shochat, Dan; Trouet, Andre
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Journal of Medicinal Chemistry (2001), 44(22), 3750-3753
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.: US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L8 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-92-4 REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-[(phenylmethoxy)carbonyl]-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C53 H67 N5 O17
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

L8 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-91-3 REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(diphenylmethyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C58 H71 N5 O15
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1998-111793P 19981211; US 1999-119312P 19990208; WO 1999-US30393 19991210; US 2000-211887P 20000614; US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462 19991210
EP 1144011	A3	20020206	

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378 19991210
AU 773420	B2	20040527	AU 2000-23733 19991210
US 2002142955	A1	20021003	US 2001-879442 20010611

PRIORITY APPLN. INFO.: US 1998-111793P 19981211; US 1999-119312P 19990208; WO 1999-US30393 19991210; US 2000-211887P 20000614; US 2001-290448P 20010511

L8 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-90-2 REGISTRY
CN 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-10-[[2,3,6-trideoxy-3-[[N-(triphenylmethyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-α-L-lyxo-hexopyranosyl]oxy]-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C64 H75 N5 O15
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.



PAGE 1-B



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1998-111793P 19981211; US 1999-119312P 19990208; WO 1999-US30393 19991210; US 2000-211887P 20000614; US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,

ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW,
AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
			US 1998-111793P	19981211
			US 1999-119312P	19990208
			WO 1999-US30393	19991210
			US 2000-211887P	20000614
			US 2001-290448P	20010511

PRIORITY APPLN. INFO.:

L8 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-89-9 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-(4-carboxy-1-oxobutyl)-β-alanyl-L-
leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-
hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-
(hydroxyacetyl)-
1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C50 H67 N5 O18
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP
(Preparation); PRP
(Properties); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.





3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER:	137:284323 CA Full-text
TITLE:	Enzyme-cleavable prodrug compounds
INVENTOR(S):	Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S):	Belg.
SOURCE:	U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN,
CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW,
AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

			US 1998-111793P	19981211
			US 1999-119312P	19990208
			WO 1999-US30393	19991210
			US 2000-211887P	20000614
			US 2001-290448P	20010511

PRIORITY APPLN. INFO.:

REFERENCE 2

ACCESSION NUMBER:	136:58787 CA Full-text
TITLE:	Enzyme-cleavable prodrug compounds
INVENTOR(S):	Nieder, Matthew H.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S):	Corixa Corporation, USA
SOURCE:	PCT Int. Appl., 159 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095945	A2	20011220	WO 2001-US18903	20010611
WO 2001095945	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE,
CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1294405	A2	20030326	EP 2001-950291	20010611

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004510703	T2	20040408	JP 2002-510122	20010611
			US 2000-211887P	20000614
			US 2001-290448P	20010511
			WO 2001-US18903	20010611

PRIORITY APPLN. INFO.:

REFERENCE 3

ACCESSION NUMBER:	133:48878 CA Full-text
TITLE:	Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S):	Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S):	Coulter Pharmaceutical, Inc., USA
SOURCE:	PCT Int. Appl., 125 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN,
CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW,
AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,

BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
			US 1998-111793P	19981211
			US 1999-119312P	19990208
			WO 1999-US30393	19991210
			US 2000-211887P	20000614
			US 2001-290448P	20010511

PRIORITY APPLN. INFO.:

L8 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2004 ACS on STN
RN 177953-52-5 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[(β-alanyl-L-leucyl-L-alanyl-L-leucyl)amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)- (9CI)
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-(N-β-alanyl-L-leucyl)-L-alanyl]-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C45 H61 N5 O15
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC
(Process); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); USES
(Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.





4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 1998-111793P	19981211
US 1999-119312P	19990208
WO 1999-US30393	19991210
US 2000-211887P	20000614
US 2001-290448P	20010511

REFERENCE 2

ACCESSION NUMBER: 135:116741 CA Full-text
TITLE: Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies
AUTHOR(S): Trouet, Andre; Passioukov, Alexandre; Van derpoorten, Kim; Fernandez, Anne-Marie; Abarca-Quinones, Jorge; Baurain, Roger; Lobl, Thomas J.; Oliyai, Cecilia; Shochat, Dan; Dubois, Vincent
CORPORATE SOURCE: Laboratory of Cell Biology, Universite Catholique de Louvain, Louvain-la-Neuve, B-1348, Belg.
SOURCE: Cancer Research (2001), 61(7), 2843-2846
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611
			US 1998-111793P	19981211
			US 1999-119312P	19990208
			WO 1999-US30393	19991210
			US 2000-211887P	20000614
			US 2001-290448P	20010511

PRIORITY APPLN. INFO.:

REFERENCE 4

ACCESSION NUMBER: 125:49345 CA Full-text
TITLE: Compounds, pharmaceutical composition and diagnostic
system comprising same, and their use
INVENTOR(S): Trouet, Andre; Baurain, Roger
PATENT ASSIGNEE(S): La Region Wallonne, Belg.; Baurain, Roger
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9605863	A1	19960229	WO 1995-BE76	19950821
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
BE 1008580	A3	19960604	BE 1994-751	19940819
BE 1008581	A3	19960604	BE 1994-752	19940819
CA 2203622	AA	19960229	CA 1995-2203622	19950821
AU 9532486	A1	19960314	AU 1995-32486	19950821
AU 694546	B2	19980723		
EP 769967	A1	19970502	EP 1995-928905	19950821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10508291	T2	19980818	JP 1995-507662	19950821
NO 9700748	A	19970410	NO 1997-748	19970218
US 5962216	A	19991005	US 1997-793910	19970401
US 6342480	B1	20020129	US 1999-298330	19990423
US 2002160943	A1	20021031	US 2001-12576	20011109

PRIORITY APPLN. INFO.:
BE 1994-751 19940819
BE 1994-752 19940819
WO 1995-BE76 19950821
US 1997-793910 19970401
US 1999-298330 19990423

=>
Uploading H:\STN queries\09879442c.str



chain nodes :
1 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
ring nodes :
2 3 4 5 6 7
chain bonds :
1-5 2-9 3-10 7-8 8-11 11-12 11-13 13-14 13-18 14-15 15-16 15-17 18-19 19-20 19-21 20-22 20-31 23-28 23-24 23-32 24-25 25-26 25-27 28-29 29-30 29-34 31-32 32-33 34-35 35-36 36-37 37-38 37-39 39-40 40-41 41-42 41-43
ring bonds :
2-3 2-7 3-4 4-5 5-6 6-7
exact/norm bonds :
1-5 2-3 2-7 2-9 3-4 4-5 5-6 6-7 7-8 8-11 11-12 13-18 18-19 19-21 20-31 23-28 28-29 29-30 31-32 32-33 35-36 36-37 37-38 41-42 41-43
exact bonds :
3-10 11-13 13-14 14-15 15-16 15-17 19-20 20-22 23-24 23-32 24-25 25-26 25-27 29-34 34-35 37-39 39-40 40-41

Match level :
1:CLASS 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS

L9 STRUCTURE UPLOADED

=> s l9 sam
SAMPLE SEARCH INITIATED 11:44:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 32 TO ITERATE

100.0% PROCESSED 32 ITERATIONS 0
ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 301 TO 979
PROJECTED ANSWERS: 0 TO 0

L10 0 SEA SSS SAM L9

=> s l9 ful
FULL SEARCH INITIATED 11:44:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 658 TO ITERATE

100.0% PROCESSED 658 ITERATIONS 5
ANSWERS
SEARCH TIME: 00.00.01

L11 5 SEA SSS FUL L9

=> d his

(FILE 'HOME' ENTERED AT 11:32:37 ON 23 OCT 2004)

FILE 'REGISTRY' ENTERED AT 11:32:52 ON 23 OCT 2004
L1 STRUCTURE UPLOADED
L2 0 S L1 SAM FAM
L3 4 S L1 FUL

FILE 'HCAPLUS' ENTERED AT 11:36:28 ON 23 OCT 2004
L4 8 S L3
L5 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 11:42:07 ON 23 OCT 2004
L6 1 S L5 SAM
L7 11 S L5 FUL
L8 7 L7 NOT L3
L9 STRUCTURE UPLOADED
L10 0 S L9 SAM
L11 5 S L9 FUL

=> l11 not l3
L12 1 L11 NOT L3

=> l12 not l8

L13 1 L12 NOT L8

=> d l13 ide ibib

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 274912-88-8 REGISTRY
CN 5,12-Naphthacenedione, 8-acetyl-10-[[3-[[N-(3-carboxy-1-oxopropyl)-β-alanyl-L-leucyl-L-alanyl-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C49 H65 N5 O17
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

RELATED SEQUENCES AVAILABLE WITH SEQLINK

Absolute stereochemistry.





3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 137:284323 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Dubois, Vincent; Fernandez, Anne Marie; Gangwar, Sanjeev; Lewis, Evan; Lobl, Thomas J.; Nieder, Matthew H.; Pickford, Lesley B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Belg.
SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Appl. No. PCT/US99/30393.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002142955	A1	20021003	US 2001-879442	20010611
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

REFERENCE 2

ACCESSION NUMBER: 136:58787 CA Full-text
TITLE: Enzyme-cleavable prodrug compounds
INVENTOR(S): Nieder, Matthew H.; Dubois, Vincent; Gangwar, Sanjeev; Lobl, Thomas J.; Pickford, Leslie B.; Trouet, Andre; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: PCT Int. Appl., 159 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095945	A2	20011220	WO 2001-US18903	20010611
WO 2001095945	A3	20020815		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1294405	A2	20030326	EP 2001-950291	20010611

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004510703	T2	20040408	JP 2002-510122	20010611

PRIORITY APPLN. INFO.:
US 2000-211887P 20000614
US 2001-290448P 20010511
WO 2001-US18903 20010611

REFERENCE 3

ACCESSION NUMBER: 133:48878 CA Full-text
TITLE: Oligopeptide prodrug compounds and process for preparation thereof
INVENTOR(S): Lobl, Thomas J.; Dubois, Vincent; Fernandez, Anne-Marie; Gangwar, Sanjeev; Lewis, Evan; Nieder, Matthew H.; Trouet, Andre; Viski, Peter; Yarranton, Geoffrey T.
PATENT ASSIGNEE(S): Coulter Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033888	A2	20000615	WO 1999-US30393	19991210
WO 2000033888	A3	20011108		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1144011	A2	20011017	EP 1999-967462	19991210
EP 1144011	A3	20020206		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2003518000	T2	20030603	JP 2000-586378	19991210
AU 773420	B2	20040527	AU 2000-23733	19991210
US 2002142955	A1	20021003	US 2001-879442	20010611

PRIORITY APPLN. INFO.:
US 1998-111793P 19981211
US 1999-119312P 19990208
WO 1999-US30393 19991210
US 2000-211887P 20000614
US 2001-290448P 20010511

=> DIS HIST

(FILE 'HOME' ENTERED AT 11:32:37 ON 23 OCT 2004)

FILE 'REGISTRY' ENTERED AT 11:32:52 ON 23 OCT 2004
L1 STRUCTURE UPLOADED
L2 0 S L1 SAM FAM
L3 4 S L1 FUL

FILE 'HCAPLUS' ENTERED AT 11:36:28 ON 23 OCT 2004
L4 8 S L3
L5 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 11:42:07 ON 23 OCT 2004
L6 1 S L5 SAM
L7 11 S L5 FUL
L8 7 L7 NOT L3
L9 STRUCTURE UPLOADED
L10 0 S L9 SAM
L11 5 S L9 FUL
L12 1 L11 NOT L3
L13 1 L12 NOT L8

=>

=>
Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY
SESSION
FULL ESTIMATED COST 334.34
544.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY
SESSION
CA SUBSCRIBER PRICE 0.00
5.60

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:45:03 ON 23 OCT 2004